The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

UK BROKER RATINGS SUMMARY: Goldman Sachs Cuts Next To Neutral From Buy

Mon, 11th May 2020 09:33

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

----------

FTSE 100

----------

GOLDMAN SACHS CUTS NEXT TO 'NEUTRAL' ('BUY') - PRICE TARGET 5300 PENCE

----------

JEFFERIES RAISES ASTRAZENECA PRICE TARGET TO 8,000 (7,575) PENCE - 'HOLD'

----------

BRYAN GARNIER RAISES ASTRAZENECA PRICE TARGET TO 8,780 (8,550) PENCE - 'BUY'

----------

CREDIT SUISSE CUTS EASYJET PRICE TARGET TO 746 (945) PENCE - 'OUTPERFORM

----------

MORGAN STANLEY CUTS LAND SECURITIES PRICE TARGET TO 740 (880) PENCE - 'OVERWEIGHT'

----------

MORGAN STANLEY CUTS BRITISH LAND PRICE TARGET TO 450 (540) PENCE - 'OVERWEIGHT'

----------

MORGAN STANLEY RAISES SEGRO PRICE TARGET TO 980 (950) PENCE - 'OVERWEIGHT'

----------

HSBC RAISES CARNIVAL TO 'BUY' ('HOLD') - TARGET 1280 (3500) PENCE

----------

BERENBERG RAISES OCADO PRICE TARGET TO 2225 (1725) PENCE - 'BUY'

----------

BERENBERG RAISES ST JAMES'S PLACE PRICE TARGET TO 875 (830) PENCE - 'HOLD'

----------

JPMORGAN CUTS RIO TINTO PRICE TARGET TO 4560 (4730) PENCE - 'NEUTRAL'

----------

JPMORGAN CUTS BHP GROUP PRICE TARGET TO 1780 (1830) PENCE - 'OVERWEIGHT'

----------

JPMORGAN CUTS ROLLS-ROYCE PRICE TARGET TO 155 (175) PENCE - 'UNDERWEIGHT'

----------

FTSE 250

----------

MORGAN STANLEY CUTS HAMMERSON TO 'UNDERWEIGHT' ('EQUAL-WEIGHT') - TARGET 50 (175) PENCE

----------

MORGAN STANLEY RAISES LONDONMETRIC PROPERTY TO 'EQUAL-WEIGHT' ('UNDERWEIGHT') - TARGET 200 (210) PENCE

----------

MORGAN STANLEY CUTS SHAFTESBURY PRICE TARGET TO 610 (770) PENCE - 'UNDERWEIGHT'

----------

MORGAN STANLEY CUTS GREAT PORTLAND PRICE TARGET TO 720 (920) PENCE - 'OVERWEIGHT'

----------

MORGAN STANLEY CUTS DERWENT LONDON PRICE TARGET TO 3400 (4250) PENCE - 'OVERWEIGHT'

----------

MORGAN STANLEY CUTS BIG YELLOW GROUP PRICE TARGET TO 900 (1000) PENCE - 'UNDERWEIGHT'

----------

MORGAN STANLEY RAISES IMI PRICE TARGET TO 980 (940) PENCE - 'EQUAL-WEIGHT'

----------

MORGAN STANLEY CUTS UNITE GROUP PRICE TARGET TO 950 (1300) PENCE - 'OVERWEIGHT'

----------

UBS RAISES TRAVIS PERKINS PRICE TARGET TO 1070 (1040) PENCE - 'NEUTRAL'

----------

HSBC CUTS WEIR GROUP TO 'HOLD' ('BUY') - TARGET 985 (1045) PENCE

----------

JPMORGAN CUTS BODYCOTE PRICE TARGET TO 530 (615) PENCE - 'NEUTRAL'

----------

GOLDMAN CUTS TATE & LYLE PRICE TARGET TO 740 (770) PENCE - 'BUY'

----------

OTHER MAIN MARKET AND AIM

----------

BERNSTEIN RAISES BOOHOO TO 'OUTPERFORM' ('MARKET-PERFORM') - TARGET 415 PENCE

----------

BERENBERG CUTS AA PRICE TARGET TO 20 (30) PENCE - 'SELL'

----------

BERENBERG RAISES BURFORD CAPITAL PRICE TARGET TO 820 (810) PENCE - 'BUY'

----------

RBC CUTS SPIRE HEALTHCARE TO 'SECTOR PERFORM' ('OUTPERFORM') - TARGET 100 PENCE

----------

Copyright 2020 Alliance News Limited. All Rights Reserved.

Related Shares

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsort...

3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out...

2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for pr...

2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood canc...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.